FDA recalls Milrinone injectable medication due to lack of sterility assurance
Sentara Infusion Services recalls 83 bags of Milrinone injectable medication nationwide due to lack of sterility assurance. Patients should contact their healthcare provider immediately.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for lack of sterility assurance in injectable medication. This constitutes a risk-of-harm product with no reported illnesses or injuries, warranting High severity per rubric criteria.
Plain-English summary
Sentara Infusion Services is recalling multiple formulations of Milrinone injectable medication due to lack of sterility assurance. The affected products consist of 83 bags in various strengths ranging from 44 mg to 192 mg, formulated in 0.45% sodium chloride solution. These products were dispensed to patients nationwide with Beyond Use Dates of December 24-31, 2022.
The recall was initiated due to deficiencies in sterility assurance processes. While no illnesses or injuries have been reported to date, failure of sterility assurance in injectable medications poses a potential health risk.
Patients who received Milrinone from Sentara Infusion Services should contact their healthcare provider immediately. Healthcare providers should verify whether affected medication was dispensed to their patients and take appropriate action regarding patient care and medication disposal.
The recalled product
- Product
- Milrinone (a) 104MG IN 0.45% NS 130ML,(b) 108MG IN 0.45% NS 135ML, (c) 120MG IN 0.45% NS 150ML, (d) 136MG IN 0.45% NS 170ML, (e) 144MG IN 0.45% NS 180ML, (f) 160MG IN 0.45% NS 200ML, (g) 168MG IN 0.45% NS 210ML, (h) 192MG IN 0.45% NS 240ML, (i) 44MG IN 0.45% NS 55 ML, (j) 52MG IN
- Manufacturer
- Sentara Infusion Services
- Category
- Drug — Injectable Medication
- Hazard
- sterility-assurance
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Beyond Use Date: December 24-31
- 2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- HighLacosamide 100mg Tablets Recalled Due to Foreign Tablet Contamination
FDA (Drugs) · 2026-07-01
- ModerateCorlanor Ivabradine Tablets Recalled for Foreign Substance Contamination
FDA (Drugs) · 2026-07-01